Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 11—November 2004


Evaluating Human Papillomavirus Vaccination Programs

Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡Comments to Author 
Author affiliations: *Stanford School of Medicine, Stanford, California, USA; †Stanford University, Stanford, California, USA; ‡Duke University, Durham, North Carolina, USA

Main Article

Table 3

Reduction in lifetime risk of cervical cancer

Cohort % reduction in lifetime
risk of cervical cancer
Full potential of program in 12-year-old girls 64
First cohort of 12-year-old girls vaccinateda 46
24-year-old women who receive catch-up vaccinationb 35
30-year-old women who receive catch-up vaccinationb 17

aThis group experiences a lower reduction in cancer cases because many of their sex partners will be drawn from a population pool that has not been vaccinated.
b24- or 30-year-old women who opt for catch-up vaccination in the first year that the vaccine becomes available.

Main Article